...
首页> 外文期刊>Prostate Cancer and Prostatic Diseases >Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures
【24h】

Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures

机译:蛋白酶体抑制剂及其与抗雄激素的组合:对前列腺腺癌细胞培养的凋亡,细胞增殖和活力的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The 26S proteasome is a ubiquitin-dependent proteolytic system that has been implicated in the regulation of cell cycle progression and apoptosis. We investigated the effects of the proteasome inhibitors MG115 and PSI alone or in combination with different concentrations of the antiandrogen hydroxyflutamide on the cellular proliferation, apoptosis and viability of 10 prostatic adenocarcinoma cell cultures. Treatment with both proteasome inhibitors resulted in apoptosis induction, whereas the combinations with hydroxyflutamide generally did not, with the exception of MG115 combined with 10-7M hydroxyflutamide. MG115 caused a significant decrease in cellular proliferation, as did the combinations of both proteasome inhibitors with hydroxyflutamide, whereas hydroxyflutamide alone was only effective at a concentration of 10-5M. Cellular viability was significantly reduced when both proteasome inhibitors were combined with 10-5M hydroxyflutamide. Although the results varied among different cell lines, we conclude that proteasome inhibitors are able to induce apoptosis and reduce cellular proliferation. They might prove effective as antineoplastic substances in prostatic adenocarcinoma alone or in combination with antiandrogens.
机译:26S蛋白酶体是一种遍在蛋白依赖性蛋白水解系统,已参与细胞周期进程和细胞凋亡的调控。我们研究了蛋白酶体抑制剂MG115和PSI单独或与不同浓度的抗雄激素羟基氟他胺合用对10种前列腺腺癌细胞培养的细胞增殖,凋亡和生存能力的影响。两种蛋白酶体抑制剂的治疗均能诱导细胞凋亡,而与羟氟他胺联合使用通常不会,但MG115与10-7M羟氟他胺联合使用除外。 MG115引起细胞增殖的显着降低,这两种蛋白酶抑制剂与羟基氟他胺的组合也是如此,而单独的羟基氟他胺仅在10-5M的浓度下有效。当两种蛋白酶体抑制剂与10-5M羟基氟他胺合用时,细胞活力显着降低。尽管结果在不同细胞系之间有所不同,但我们得出结论,蛋白酶体抑制剂能够诱导细胞凋亡并减少细胞增殖。它们可能被单独或与抗雄激素联合使用作为抗癌物质在前列腺腺癌中有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号